JGC
PTGX icon

J. Goldman & Co’s Protagonist Therapeutics PTGX Stock Holding History

J. Goldman & Co’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.15M Sell
9,414
-300
-3% -$31.3K 0.03% 427
2026
Q1 		$1.02M Sell
9,714
-36,611
-79% -$3.24M 0.03% 414
2025
Q4 		$4.05M Buy
46,325
+28,257
+156% +$2.31M 0.11% 226
2025
Q3 		$1.2M Sell
18,068
-17,760
-50% -$1.01M 0.03% 318
2025
Q2 		$1.98M Sell
35,828
-29,416
-45% -$1.41M 0.05% 277
2025
Q1 		$3.16M Buy
+65,244
New +$2.73M 0.08% 251
2022
Q2 		– Sell
-81,873
Closed -$1.94M – 442
2022
Q1 		$1.94M Sell
81,873
-48,644
-37% -$1.37M 0.09% 206
2021
Q4 		$4.46M Buy
+130,517
New +$4.13M 0.25% 117
2021
Q3 		– Sell
-19,986
Closed -$897K – 438
2021
Q2 		$897K Sell
19,986
-29,593
-60% -$977K 0.03% 287
2021
Q1 		$1.28M Buy
49,579
+11,238
+29% +$284K 0.04% 282
2020
Q4 		$773K Buy
38,341
+15,125
+65% +$326K 0.04% 254
2020
Q3 		$454K Sell
23,216
-26,143
-53% -$491K 0.03% 257
2020
Q2 		$872K Buy
+49,359
New +$619K 0.05% 201

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

J. Goldman & Co's PTGX Position: Q2 2026 in Review

J. Goldman & Co reduced its Protagonist Therapeutics (PTGX) stake by 3.1% in Q2 2026, selling an estimated $31.3K and leaving 9,414 shares worth $1.15M. The position accounts for 0.03% of the portfolio, ranked #427.

J. Goldman & Co first reported a position in PTGX in Q2 2020 and has held it in 13 quarters since. The position peaked at $4.46M in Q4 2021. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • J. Goldman & Co held 9,414 shares of Protagonist Therapeutics worth $1.15M as of Q2 2026.
  • J. Goldman & Co sold 300 Protagonist Therapeutics shares in Q2 2026, an estimated $31.3K.
  • Protagonist Therapeutics made up 0.03% of J. Goldman & Co's portfolio in Q2 2026, its #427 holding.
  • J. Goldman & Co first reported a position in Protagonist Therapeutics in Q2 2020 and has held it in 13 quarters since.
  • J. Goldman & Co's Protagonist Therapeutics position peaked at $4.46M in Q4 2021.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on J. Goldman & Co's 13F filing for Q2 2026, filed 14 Aug 2026.